AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

LANREOTIDE

11 registrations across 2 African markets— 8 active

Markets with LANREOTIDE

Recent registrations

Brand / ProductMarketHolderStatusExpires
SOMATULINE LP
Solution injectable / 60 mg
🇹🇳TunisiaIPSEN PharmaexpiredMar 2017
SOMATULINE LP
Solution injectable / 90 mg
🇹🇳TunisiaIPSEN PharmaexpiredMar 2017
SOMATULINE LP
Solution injectable / 120 mg
🇹🇳TunisiaIPSEN PharmaexpiredMar 2017
SOMATULINE LP 120 MG
SOLUTION INJECTABLE LP
🇲🇦Moroccoactive
SOMATULINE LP 120 MG
SOLUTION INJECTABLE LP
🇲🇦Moroccoactive
SOMATULINE LP 30 MG
SOLUTION INJECTABLE
🇲🇦Moroccoactive
SOMATULINE LP 30 MG
SOLUTION INJECTABLE
🇲🇦Moroccoactive
SOMATULINE LP 60MG
SOLUTION INJECTABLE LP
🇲🇦Moroccoactive
SOMATULINE LP 60MG
SOLUTION INJECTABLE LP
🇲🇦Moroccoactive
SOMATULINE LP 90 MG
SOLUTION INJECTABLE LP
🇲🇦Moroccoactive
SOMATULINE LP 90 MG
SOLUTION INJECTABLE LP
🇲🇦Moroccoactive

LANREOTIDE in Africa — Regulatory Overview

LANREOTIDE is registered across 2 African markets with 11 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Morocco, Tunisia. AfricaRegulatory refreshes this data daily from official government sources.

Of the 11 registrations, 8 (73%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.